Targeting MCL-1/BCL-X(L) Forestalls the Acquisition of Resistance to ABT-199 in Acute Myeloid Leukemia

ABT-199, a potent and selective small-molecule antagonist of BCL-2, is being clinically vetted as pharmacotherapy for the treatment of acute myeloid leukemia (AML). However, given that prolonged monotherapy tends to beget resistance, we sought to investigate the means by which resistance to ABT-199...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Sci Rep
Autors principals: Lin, Kevin H., Winter, Peter S., Xie, Abigail, Roth, Cullen, Martz, Colin A., Stein, Elizabeth M., Anderson, Gray R., Tingley, Jennifer P., Wood, Kris C.
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2016
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4901329/
https://ncbi.nlm.nih.gov/pubmed/27283158
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/srep27696
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars